Imara Inc reports results for the quarter ended in December - Earnings Summary

Enliven Therapeutics

15/03/2022 13:32

* Imara Inc  IMRA.OQ  reported a quarterly adjusted loss
of 53
cents​​ per share for the quarter ended in December. The mean
expectation of four analysts for the quarter was for a loss
of 75 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * The mean earnings estimate of analysts had fallen by
about 8.6%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Imara Inc shares had fallen by 36.0% this quarter.
    * Wall Street's median 12-month price target for Imara Inc
is
$16.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 15 at 01:32 p.m.  ​All
figures in US dollars unless otherwise stated